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In 2012, the UK funder, the National Institute for Health Research (NIHR), in response to 
delays in research for 2009 influenza A/H1N, funded a portfolio of nine projects, described in 
a Personal View [1]. They were put on standby mode in a maintenance-only state awaiting 
activation in the event of new pandemic influenza. The portfolio covered key pathways of 
healthcare, including surveillance, primary prevention, triage and clinical management. In 
2018 we were requested to adapt projects for new and emerging infectious diseases. Eight of 
nine projects have been repurposed and activated in response to the COVID-19 pandemic. 
 
Flu Telephone Survey Template study (FluTEST), the first study to be activated is a survey 
of public knowledge, attitudes and behaviour and has been evaluating the impact of official 
communications on behaviour change in the community (table 1). The Early estimation of 
pandemic influenza Antiviral and Vaccine Effectiveness (EAVE) study has been expanded 
with data from 1.5m patients and the addition of new datasets including hospital ePrescribing. 
Potential therapies and the natural history of COVID-19 are to be explored. FLU-CATS, a 
real-time refinement and validation of criteria in primary care to aid hospital referral has been 
adapted to gather data from possible COVID-19 cases including gathering data from 
telephone consultations. The ISARIC WHO Clinical Characterisation Protocol for emerging 
infections UK (CCP-UK) study facilitates the collection of standardised clinical data and 
samples on patients hospitalised with suspected or confirmed infection with COVID-19. 
Funded by MRC, recruitment to CCP-UK has exceed 3,250 cases and samples are being 
distributed [2]. Data from CCP-UK is supporting Scientific Pandemic Influenza Modelling 
Committee (SPI-M)  and the Scientific Advisory Group for Emergencies (SAGE). PAINTED 
has become the PRIEST Study: Pandemic Respiratory Infection Emergency System Triage, 
reflecting expansion to include all pandemic respiratory infections and the involvement of the 
ambulance service, alongside the emergency department, in deciding who needs hospital 
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admission. The UKOSS pregnancy study has been activated, no alterations to the study, other 
the change to collection of data on COVID-19 infection have been needed. The 
Dexamethasone arm of RECOVERY (www.recoverytrial.net) is effectively an adaptation of 
The Multi-centre Adjuvant Steroids in Adults with Pandemic Influenza (ASAP) Trial. The 
first patient was recruited to the Trial within two weeks of the declaration of a pandemic by 
WHO (on 11 March 2020). The RTM Trial had been activated prior to COVID-19 pandemic, 
creating real time models to predict the impact of seasonal influenza [3]. More recently, our 
model has been adapted to COVID-19 and has been assisting SAGE through SPI-M. 
Decisions were guided through simulation of possible scenarios (in February) and now 
estimating epidemic evolution from initial data on confirmed cases and deaths. These 
estimates are being used to predict ICU demand, both nationally and at regional level. The 
PIPS study has not been activated as The Health Survey for England has cancelled field work 
due to social distancing measures. This has made the timely collection of specimens for 
serology not possible. 
 
This national portfolio of hibernated pandemic studies is illustrating the value of the UKs 
clinical research system and the potential for rapid research, as well as clinical and public 
health response, to this pandemic. That most studies have been activated, and are performing 
well, exemplifies this model as an optimal way of using hibernating research studies to 
prepare for pandemic and emerging infections. 
 
Contributors: CS led the writing of this personal view. All authors made contributions to the 
writing and discussions on scope and critically reviewed revisions. 
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Table 1 National Institute of Health Research Pandemic Preparedness Portfolio  COVID-19 pivot 
Project 
Lead Applicant 
and Institute 
Purpose of study Pivot to COVID-19 and status Link 
Flu Telephone Survey 
Template study (FluTEST) 
Dr James Rubin, 
Kings College 
London 
Survey to identify public knowledge, attitudes and 
behaviour. During a pandemic we will support the 
UK Department of Health and Social Care in 
deploying these items and interpreting the results. 
The first study to be activated. No 
substantial changes and findings 
being used to inform public health 
strategies. Study in progress. 
https://www.ncbi.nlm
.nih.gov/books/NBK
263566  
Early estimation of 
pandemic influenza 
Antiviral and Vaccine 
Effectiveness (EAVE): use 
of a unique community and 
laboratory national linked 
dataset 
Professor Colin 
Simpson, The 
University of 
Edinburgh 
Sentinel system linking primary care data to RT-
PCR swabs, serology and hospital and mortality 
outcome data. Rapid evaluation of vaccination, 
antivirals and therapies. Intelligence on groups 
considered to be at increased risk of serious illness 
or death from infection. 
Increase in country-wide population 
coverage and new datasets (including 
A&E, ambulance, ICU and 
ePrescribing). COVID-19 related 
morbidity and therapy data added. 
Therapeutic effectiveness and natural 
history of COVID-19 to be explored. 
Undergoing ethical and privacy 
permissions via substantial 
amendment of EAVE permissions.  
https://www.ncbi.nlm
.nih.gov/books/NBK
321438  
Real time refinement and 
validation of criteria and 
tools used in primary care to 
aid hospital referral 
decisions for patients of all 
ages in the event of surge 
during an influenza 
pandemic - FLU-CATs 
(Influenza Community 
Assessment Tools) 
Professor  Calum 
Semple, University 
of Liverpool 
FLU-CATs is a study that checks if decision tools 
can be used by GPs and other Health Care 
Professionals to help them choose who can be cared 
for safely in the community and who needs urgent 
referral to hospital. FLU-CATs runs each winter 
influenza season in a small number of GP practices 
to keep the study processes running smoothly and 
ready to react should there be a new influenza 
outbreak. In the event of a new influenza outbreak 
FLU-CATs will quickly identify which problems 
that patients have best predict the level of care that 
they need. 
 
Adapted to gather data from possible 
COVID-19 cases. Gathering data 
from telephone consultations. Study 
underway. 
https://www.nottingh
am.ac.uk/research/gr
oups/healthprotection
/projects/flu-
cats.aspx 
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International Severe Acute 
Respiratory and emerging 
Infection Consortium 
(ISARIC) WHO Clinical 
Characterisation Protocol for 
emerging infections UK 
(CCP-UK)  
 
Professor  Calum 
Semple, University 
of Liverpool 
Provides an ethically approved framework for 
enrolling patients to a clinical study which offers 
new insights into this emerging global threat. It 
facilitates the collection of standardised clinical data 
and samples on patients hospitalised with suspected 
or confirmed infection with COVID-19. This 
informs the outbreak response and patient care. 
COVID-19 patients now identified in the UK, the 
UK health research community is well-prepared to 
advance our understanding of this disease. 
Over 3250 COVID-19 cases recruited 
(as of 31/03/2020). Data and samples 
are being distributed. Reporting 
automated analysis in real-time to 
Scientific Pandemic Influenza 
Modelling group (SPI-M), the New 
Emerging Respiratory Virus Threats 
Advisory Group (NERVTAG) and 
Scientific Advisory Group for 
Emergencies  (SAGE) 
 
PAndemic INfluenza Triage 
in the Emergency 
Department (The PAINTED 
study) 
Professor Steve 
Goodacre, 
University of 
Sheffield 
PAINTED aims to identify the most accurate triage 
method for predicting severe illness among patients 
attending the emergency department with suspected 
pandemic influenza.   
Changed to PRIEST (Pandemic 
Respiratory Infection Emergency 
System Triage) to include all 
pandemic respiratory infections and 
include ambulance services.  
Status  study in progress following 
expedited ethics and regulatory 
review of amended protocol. 
https://www.sheffield
.ac.uk/scharr/sections
/hsr/cure/priestpages/
priest 
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Maternal and perinatal 
outcomes of pandemic 
influenza in pregnancy 
(UKOSS) 
Professor Marian 
Knight, University 
of Oxford 
The UKOSS influenza in pregnancy study will use 
an existing research platform to collect information 
on pregnant and postpartum women admitted to 
hospital with confirmed influenza infection. The 
management of women will be described, focussing 
particularly on the role of extracorporeal membrane 
oxygenation (ECMO), and women will be followed 
up to pregnancy completion in order to collect 
information on both maternal and perinatal 
outcomes. 
Collecting information on 
pregnant/postpartum women with 
COVID-19. Study has begun  no 
known issues at this stage.  
https://www.npeu.ox.
ac.uk/ukoss/current-
surveillance/flu  
Multi-centre Adjuvant 
Steroids in Adults with 
Pandemic Influenza (ASAP) 
Trial 
Professor Wei Shen 
Lim, Nottingham 
University 
Hospitals 
The ASAP trial is a multicentre (>40 sites) blinded 
randomised controlled clinical trial to determine if 
low dose corticosteroids (dexamethasone 6mg 
started within 24 hours of admission once a day for 
5 days), in addition to standard care, is associated 
with a lower risk of death or admission to intensive 
care, compared to placebo.  
 
The ASAP trial has become an arm 
of RECOVERY. Research sites at 
hospitals are completing training and 
once the intervention drugs are 
available (Kaletra, INFbeta, low-dose 
Dexamethasone) recruitment will 
begin.  
https://asaptrial.org/ 
www.recoverytrial.ne
t 
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Real-time Modelling of a 
Pandemic Influenza 
Outbreak (RTM) 
Professor Daniela 
De Angelis 
University of 
Cambridge 
The real time model (RTM) project advances real 
time pandemic modelling by developing an existing 
model used to reconstruct the 2009 H1N1 pandemic 
on the basis of realistic epidemic surveillance data 
collected. A monitoring tool that allows to: capture 
spatial variation in influenza transmission; uses 
efficient computational algorithms for the provision 
of timely statistical estimates and predictions; and 
incorporates the above into freely available 
software. The tool is used by Public Health England, 
and key staff has been trained in its use, supported 
by collaborators at the University of Cambridge to 
deal with workforce shortage during a pandemic. 
The real time model has been tested in the 
monitoring of the 2017/2018 seasonal influenza and 
ready to be used in the current season to estimate 
infection and clinical attack rates and to predict 
timing and magnitude of the peak influenza activity. 
 
Adapted to assist the Scientific 
Pandemic Influenza Advisory 
Committee (SPIM) and SAGE via 
simulation and estimation of 
epidemic evolution to predict ICU 
demand (National and Regional). 
Was activated prior to pandemic 
COVID-19 to create real-time models 
predicting the impact of seasonal 
influenza. 
https://www.ncbi.nlm
.nih.gov/books/NBK
458958/pdf/Bookshel
f_NBK458958.pdf  
The population-level 
susceptibility, severity and 
spread of pandemic 
influenza study (PIPS) 
Professor Andrew 
Hayward, 
University College 
London 
Rapid assessment of real-time community-level 
susceptibility and spread of infection and illness in 
the event of a pandemic. Achieved this by adding 
additional questions and specimen collection to the 
Health Survey for England, an annual, nationally-
representative survey that recruits participants 
throughout the year. 
 
Not activated. The Health Survey for 
England has cancelled field work 
during the recommended period of 
social distancing making timely 
collection of specimens for serology 
not possible through this period. 
https://www.ncbi.nlm
.nih.gov/books/NBK
299604/pdf/Bookshel
f_NBK299604.pdf  
 
